Diovan soon to be top anti-hypertension drug in Korea.
Novartis Korea said on May 4 that in competition with Cozaar and Aprovel in the ARB anti-hypertension drug markets Diovan would get the top seller soon, which was already a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
